早期大剂量辛伐他汀对老年急性冠脉综合征hs-CRP影响.doc

早期大剂量辛伐他汀对老年急性冠脉综合征hs-CRP影响[摘要] 目的 观察大剂量辛伐他汀降脂对老年急性冠脉综合征的高敏C反应蛋白影响。方法 选取2007～2009年我院老年急性冠脉综合征患者随机分为两组：早期应用辛伐他汀40mg/d、常规辛伐他汀20mg/d，检测两组血清高敏C反应蛋白（hs-CRP）及血脂并观察两组辛伐他汀对其影响。结果 两组治疗后血清hs-CRP比较差异有统计学意义（P＜0.05）。结论 ACS患者应用20mg/d及40mg/d的辛伐他汀均能有效降低hs-CRP及血脂，40mg/d辛伐他汀降hs-CRP及减少心血管事件作用更佳，老年急性冠脉综合征强化早期降脂，可减少终点的发生率。 [关键词] 老年急性冠脉综合征；辛伐他汀；高敏C反应蛋白 [中图分类号] R541.4 [文献标识码] B [文章编号] 1673-9701（2011）21-43-02 Impacts of Early-stage Large-dose Simvastatin on High Sensitive C-reactive Protein of Elderly Acute Coronary Syndrome DAI Shaoying Internal Medicine Department，Xiangshan County Traditional Chinese Medicine Hospital in Zhejiang Province，Xiangshan 315700，China [Abstract] Objective To observe the impact of blood lipid reduction by large-does Simvastatin on the high C-reactive protein of elderly acute coronary syndrome. Methods Divide elderly acute coronary syndrome patients admitted in our hospital from 2007 to 2009 into two groups，one group was treated with Simvastatin 40mg/d and the other group with conventional 20mg/d Simvastatin. We examined their serum high sensitive CRP（hs-CRP） and blood lipid and observed the impact of Simvastatin on both groups. Results The differences of serum hs-CRP in the two groups had statistical significance（P＜0.05）. Conclusion For ACS patients，both 20mg/d and 40mg/d Simvastatin are effective on reducing hs-CRP and blood lipid，40mg/d Simvastatin has better effects in reducing hs-CRP and cardiovascular incidents. Reducing blood lipid of elderly acute coronary syndrome at early stage can help reduce terminal occurrence rate. [Key words] Elderly cute coronary syndrome；Simvastatin；hs-CRP 急性冠状动脉综合征（ACS）与斑块内炎症反应密切相关，而高敏C反应蛋白（hs-CRP）作为炎症反应的重要标志物，是导致心血管疾病的独立危险因素，也是心血管事件的独立强预测因子[1]。研究证实了他汀类药物治疗可以减少冠心病事件的发生，并减少冠心病死亡率和总死亡率，hs-CRP水平升高是冠心病严重并发症的预测因子和独立危险因素之一，我们检测了老年ACS患者血清CRP及血脂，并观察两种不同剂量调脂药物辛伐他汀对其的影响。 1资料与方法 1.1一般资料 选取我院2007～2009年住院的老年ACS患者102例，其中急性心梗75例，不稳定心绞痛27例，102例入院前1个月内均未服用降脂药物，均无感染性疾病及免疫性疾病。将患者随机分为两组，在常规治疗的基础上分别给予口服辛伐他汀（商品名：京必舒新，